![Wills Hughes-Wilson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Wills Hughes-Wilson
Corporate Officer/Principal chez
MEREO BIOPHARMA GROUP PLC
Fortune : 17 363 $ au 31/05/2026
Profil
Alexandra Hughes-Wilson is Chief Patient Access & Commercial Planning at Mereo BioPharma Group Plc since 2018.
Former roles include Chief Patient Access Officer & Senior VP at Swedish Orphan Biovitrum AB from 2016 to 2018, Executive Director at European Biopharmaceutical Enterprises, Vice President-Health & Market Access Policy at Genzyme Corp., and VP-Health & Market Access Policy EMEA at Genzyme Therapeutics Ltd. Education includes a graduate degree from the University of Durham.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/02/2026 | 252 375 ( 0,03 % ) | 17 363 $ | 31/05/2026 |
Postes actifs de Wills Hughes-Wilson
| Sociétés | Poste | Début |
|---|---|---|
| MEREO BIOPHARMA GROUP PLC | Corporate Officer/Principal | 01/03/2018 |
Anciens postes connus de Wills Hughes-Wilson
| Sociétés | Poste | Fin |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Public Communications Contact | 01/01/2018 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Corporate Officer/Principal | - |
European Biopharmaceutical Enterprises
 European Biopharmaceutical Enterprises BiotechnologyHealth Technology Develops biological products | Directeur/Membre du Conseil | - |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | - |
Formation de Wills Hughes-Wilson
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
35
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
University of Durham
 University of Durham Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
European Biopharmaceutical Enterprises
European Biopharmaceutical Enterprises BiotechnologyHealth Technology Develops biological products | Health Technology |
Swedish Orphan Biovitrum AB
 Swedish Orphan Biovitrum AB Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceuticals and orphan drugs in the areas of hematology, immunology and specialty care | Health Technology |
Mereo BioPharma Group Plc
 Mereo BioPharma Group Plc BiotechnologyHealth Technology Operates as a biopharmaceutical company | Health Technology |
